Pharmaceutical giant AbbVie has unveiled plans to invest $380 million in the construction of two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago site in Illinois. This project marks another step in the company’s $100 billion commitment to R&D and capital investments in the United States over the next decade.
The new facilities will feature advanced manufacturing technologies and Artificial Intelligence (AI) to optimize complex multi-step chemical synthesis processes. These plants will specifically support the production of AbbVie’s obesity medications and next-generation neuroscience treatments. Construction is scheduled to begin in the spring of 2026, with full operations expected by 2029, creating approximately 300 new positions for engineers, scientists, and technicians.
This investment aligns with AbbVie’s broader strategy to relocate the production of key neuroscience, immunology, and oncology APIs from Europe and Asia back to the U.S. In addition to the Chicago expansion, the company is also growing its manufacturing footprint in Arizona and Massachusetts, underscoring its commitment to enhancing domestic supply chain resilience and driving medical innovation.
Source: https://www.pharmaceutical-technology.com/news/abbvie-investment-north-chicago-api/?cf-view